Therapeutic monoclonal antibodies are now approaching maturity and constitute the fastest growing market representing more than 30% of the global biologic drug market. On the other hand with the advent of the biosimilars and the success of enzyme replacement therapy products, recombinant proteins play a pivotal role in the biopharmaceutical market.

areta was born as a manufacturer of antibodies and rapidly extended the portfolio of services to recombinant proteins, being able to develop, scale-up and produce proteins and antibodies with great quality and flexibility.

areta can deliver you formulated and fully characterized antibodies and proteins obtained from eukaryotic or prokaryotic cells in the liquid or lyophilized forms.